Tyra Biosciences, Inc. (NASDAQ:TYRA) Shares Acquired by Millennium Management LLC

Millennium Management LLC grew its position in Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) by 2,900.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 315,141 shares of the company's stock after acquiring an additional 304,637 shares during the period. Millennium Management LLC owned about 0.62% of Tyra Biosciences worth $4,380,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in TYRA. KLP Kapitalforvaltning AS purchased a new stake in shares of Tyra Biosciences in the fourth quarter valued at about $31,000. US Bancorp DE acquired a new stake in shares of Tyra Biosciences in the fourth quarter valued at about $50,000. BNP Paribas Financial Markets acquired a new stake in shares of Tyra Biosciences in the fourth quarter valued at about $60,000. Aquatic Capital Management LLC acquired a new stake in shares of Tyra Biosciences in the fourth quarter valued at about $64,000. Finally, Wells Fargo & Company MN lifted its stake in shares of Tyra Biosciences by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 9,493 shares of the company's stock valued at $132,000 after purchasing an additional 3,236 shares during the period. Hedge funds and other institutional investors own 84.14% of the company's stock.

Tyra Biosciences Price Performance

TYRA remained flat at $9.25 during midday trading on Friday. 557,503 shares of the company's stock were exchanged, compared to its average volume of 267,571. The firm has a market cap of $491.08 million, a PE ratio of -5.75 and a beta of 1.17. The company's fifty day moving average price is $9.26 and its 200-day moving average price is $12.34. Tyra Biosciences, Inc. has a one year low of $6.42 and a one year high of $29.60.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. Equities analysts predict that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on TYRA. Piper Sandler began coverage on shares of Tyra Biosciences in a research note on Wednesday, May 21st. They issued an "overweight" rating and a $33.00 price objective for the company. Wedbush reiterated an "outperform" rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research note on Friday, March 28th. Finally, HC Wainwright reiterated a "buy" rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research note on Monday, March 31st. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Tyra Biosciences presently has an average rating of "Buy" and a consensus target price of $30.83.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.